Disappointing PhIII results dash AstraZeneca's hopes of reviving a tarnished cancer drug through Lynparza combo
Barely a year after a team at Yale tried to make sense of some unexpected Phase II results around an ovarian cancer drug that AstraZeneca …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
